Silybum marianum in treatment and prevention of hepatotoxicity

The effect of Silybum marianum in treatment and prevention of hepatotoxicity in patients undergoing induction therapy for acute lymphoblastic leukemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014080717325N2

Enrollment

Registered

2014-08-27

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia. Acute lymphoblastic leukaemia

Interventions

Intervention 1: Silybum marianum 5 mg/kg daily for 28 day in case group. Intervention 2: Zinc sulfate 5 mg/kg daily for 28 day in control group.

Prevention

Silybum marianum 5 mg/kg daily for 28 day in case group

Zinc sulfate 5 mg/kg daily for 28 day in control group

Eligibility

Sex/Gender

All

Age

30 Days to 14 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Children aged under 15 with a diagnosis of acute lymphoblastic leukemia undergoing induction therapy Exclusion criteria: Patients with liver diseases or diabetes

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Reduces hepatotoxicity of chemotherapy. Timepoint: In first visit, Day 28, Day 56. Method of measurement: Enzymatic.	—

Secondary

Measure	Time frame
Fasting blood glucose. Timepoint: In first visit, Day 28, Day 56. Method of measurement: In first visit, Day 28, Day 56.;Side effects. Timepoint: In first visit, Day 28, Day 56. Method of measurement: In first visit, Day 28, Day 56.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZhalehRoohzendeh

Ardabil University of Medical Sciences

zhalehroohzendeh@gmail.com+98 45 3351 3228

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026